ArticleFrontiers in immunology2026
Risk stratification and multi-omics reveal RAD51 inhibition as a radiosensitizing strategy in triple-negative breast cancer.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Triple-negative breast cancer (TNBC) is a highly aggressive subtype characterized by significant inter- and intra-tumoral heterogeneity. Its varied response to radiotherapy limits clinical outcomes, yet the underlying molecular determinants remain poorly understood. Methods: By integrating single-cell and bulk transcriptomic data, we profiled cell-type-specific radiosensitivity and defined distinct molecular subtypes via consensus clustering. A random survival forest (RSF) prognostic model was then constructed using 34 survival-associated genes and interpreted via SHAP analysis, and its performance was validated in multiple independent external cohorts. RAD51 was prioritized via Dependency Map (DepMap) analysis, and its functional role was validated Results: Single-cell analysis revealed that fibroblasts, macrophages, and proliferative cells harbored elevated radioresistance signatures compared to lymphoid lineages. Bulk profiling identified two distinct subtypes: Cluster A (immunosuppressive, radioresistant, poor prognosis) and Cluster B (immune-active, favorable survival). The RSF model robustly stratified patient risk, with high-risk tumors tightly linked to an immune-desert microenvironment. DepMap analysis nominated RAD51 as a core biological dependency. Importantly, RAD51 knockdown sensitized TNBC cells to irradiation by exacerbating DNA damage, triggering G2/M phase arrest, and driving apoptosis. Consistently, Conclusion: This integrative multi-omics study delineates the cellular and molecular landscape of TNBC radioresistance. The RSF model provides a robust tool for risk stratification, while identifying RAD51 as a potential therapeutic target to restore radiosensitivity and reverse immunosuppression, particularly in high-risk, immune-cold tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.